Skip to main content
. Author manuscript; available in PMC: 2011 Feb 9.
Published in final edited form as: Circulation. 2010 Jan 25;121(5):675–683. doi: 10.1161/CIRCULATIONAHA.109.902221

Figure 8.

Figure 8

Doxorubicin treatment inhibits proliferation of isolated CPCs. Cells were treated with doxorubicin for 72 h and then assessed for (A) cell proliferation by MTT assay (n=3), and (B) cell death by Trypan Blue exclusion assay (n=3). C. Cells were treated with 100 nM doxorubicin and proliferation was determined by BrdU incorporation (n=4). D. Cells were exposed to vehicle or 100 nM DOX for 72 h or 96 h and then assayed for telomerase activity using the TRAP assay (n=3). E. Isolated CPCs were treated with 100 nM DOX for 72 h and then fixed and stained for the presence of c-kit and p16INK4a. F. Quantitation of p16INK4a positive cells (n=4).